NovoCure Files 8-K on Financial Condition & Operations

TL;DR

**NovoCure just filed an 8-K about their financial results, so watch for details.**

AI Summary

NovoCure Ltd. filed an 8-K on January 8, 2024, indicating a current report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934. The filing specifically reports on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' for the period of January 1, 2024, to January 31, 2024. This matters to investors because it signals that the company is providing an update on its financial performance and condition, which could impact stock valuation depending on the details of the results.

Why It Matters

This filing indicates NovoCure is providing an update on its financial health and performance, which is crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information, not an event that inherently carries high risk.

Analyst Insight

A smart investor would await the detailed financial statements and results mentioned in this 8-K to understand NovoCure's performance before making any investment decisions.

Key Players & Entities

• NovoCure Ltd. (company) — the registrant filing the 8-K
• The Securities Exchange Act of 1934 (other) — the act under which the filing is made
• January 8, 2024 (date) — date of report
• January 1, 2024 (date) — start of the reported period
• January 31, 2024 (date) — end of the reported period

FAQ

Filing Documents

• nvcr-20240108.htm (8-K) — 26KB
• pressreleaseprelim2023resu.htm (EX-99.1) — 17KB
• 0001645113-24-000003.txt ( ) — 172KB
• nvcr-20240108.xsd (EX-101.SCH) — 2KB
• nvcr-20240108_lab.xml (EX-101.LAB) — 23KB
• nvcr-20240108_pre.xml (EX-101.PRE) — 12KB
• nvcr-20240108_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, NovoCure Limited ( the "Company") issued a press release announcing certain preliminary financial results and providing certain other information for the quarter and year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 (the "Press Release"). The financial data contained therein are unaudited, preliminary, based upon the Company's good faith estimates and subject to completion of the Company's financial closing procedures. While the Company expects that its final financial results for the quarter and year ended December 31, 2023, following the completion of its financial closing procedures, will generally be consistent with the information provided in the Press Release, the Company's actual results may differ materially from these estimates as a result of the completion of its financial closing procedures for the quarter and year ended December 31, 2023, as well as final adjustments and other developments that may arise between now and the time that its financial results for the quarter and year ended December 31, 2023 are finalized. The information contained in item 2.02 of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: January 8, 2023 By: /s/ Ashley Cordova Name: Ashley Cordova Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR